Dapsone is a sulfone antimicrobial agent that may be used to prevent Pneumocystis jiroveci pneumonia in susceptible patients. Some patients may develop methemoglobinemia during dapsone therapy.
The risk of dapsone-induced methemoglobinemia is dose-related.
The recommended daily dose for prophylaxis of Pneumocystis is 2 mg per kg (not specified as actual or ideal).
A daily dose that is >= 120% times the recommended daily dose (>= 2.4 mg per kg) is associated with an increased risk of methemoglobinemia (hazard ratio 6.3).
A daily dose that is <= 80% of the recommended daily dose is associated with a markedly reduced risk for methemoglobinemia (hazard ratio 0.3).
To read more or access our algorithms and calculators, please log in or register.
